




ELSEVIER

Archivos de Cardiología de México

www.elsevier.com.mx



CLINICAL RESEARCH

Evaluation of clopidogrel response variability and identification of the CYP2C19 polymorphism in Mexican patients

Martha Eva Viveros^{a,*}, Carlos Areán^b, Sergio Gutiérrez^a, Soledad Vázquez^a, Mario Humberto Cardiel^c, Alejandra Taboada^a, Gissela Marín^a, Rubén Solorio^b, Nalley García^a

^a División de Estudios de Posgrado, Facultad de Ciencias Médicas y Biológicas Dr. Ignacio Chávez, Universidad Michoacana de San Nicolás de Hidalgo, Morelia, Michoacán, Mexico

^b Servicio de Cardiología Intervencionista, Hospital General Dr. Miguel Silva, Morelia, Michoacán, Mexico

^c Unidad de Investigación Dr. Mario Alvizouri, Hospital General Dr. Miguel Silva, Morelia, Michoacán, Mexico

Received 10 December 2015; accepted 28 January 2016

KEYWORDS

VASP analysis;
Clopidogrel
resistance;
High on treatment
platelet reactivity;
P2Y12;
CYP2C19*2
polymorphism;
Mexico

Abstract

Objective: Drug inhibition of platelet P2Y12 adenosine diphosphate receptor has reduced the incidence of adverse cardiovascular events after percutaneous coronary interventions. The analysis of the phosphorylation status of vasodilator-stimulated phosphoprotein by flow cytometry has shown a predictive value for adverse events and stent thrombosis. Polymorphisms of CYP2C19 in high risk patients may also relate to adverse cardiovascular events.

Methods: Ninety patients were enrolled. Patients received a 600 mg clopidogrel loading dose. Blood samples were obtained at the time of the procedure and 24 h later, platelet reactivity was assessed by vasodilator-stimulated phosphoprotein phosphorylation measurement using flow cytometry. Low response to clopidogrel was defined as a platelet reactivity index $\geq 50\%$. The presence of CYP2C19*2 was identified with the restriction enzyme *Sma*I.

Results: Mean platelet reactivity index: $53.45 \pm 22.48\%$ in the baseline sample and $57.14 \pm 23.08\%$ at 24 h ($p = 0.183$); 40% of patients behaved as good responders, the rest behaved as non-responders with 38% of patients showing platelet reactivity indexes between 50–70% and 22% showing indexes above 70%. The CYP2C19*2 polymorphism was found in 17% of patients, with a 3.9% AA homozygous genotype carriers.

* Corresponding author at: División de Estudios de Posgrado, Facultad de Ciencias Médicas y Biológicas Dr. Ignacio Chávez, Universidad Michoacana de San Nicolás de Hidalgo, Morelia, Michoacán, Mexico, Ave. Rafael Carrillo esq. Dr. Salvador González Herrejón s/n, Col. Cuahtémoc, Morelia, Michoacán, C.P. 58020, Morelia, Michoacán, Mexico. Tel.: +52 443 299 3159.

E-mail address: marthaeaviveros@yahoo.com.mx (M.E. Viveros).

Conclusion: Response to the clopidogrel loading dose showed a wide variability among patients with 40% responding to the drug according to previously established cut-off values. Our results showed that 3.9% of patients show the AA genotype. To our knowledge, this is the first study involving clopidogrel response by flow cytometry and genotype typification in Mexican Mestizo population.

© 2016 Instituto Nacional de Cardiología Ignacio Chávez. Published by Masson Doyma México S.A. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

PALABRAS CLAVE

Análisis VASP;
Resistencia a clopidogrel;
Alta reactividad plaquetaria en tratamiento;
Receptor P2Y12;
Polimorfismo CYP2C19*2;
Méjico

Evaluación de la variabilidad en la respuesta a clopidogrel e identificación del polimorfismo CYP2C19 en pacientes mexicanos

Resumen

Objetivo: La inhibición del receptor plaquetario P2Y12 se ha asociado con reducción en incidencia de eventos cardiovasculares mayores en pacientes sometidos a intervenciones coronarias percutáneas. El estudio de la fosfoproteína estimulada por vasodilatadores mediante citometría de flujo tiene valor predictivo para desarrollo de eventos adversos y trombosis del stent. Los polimorfismos del CYP2C19 en pacientes de alto riesgo pueden también asociarse con eventos adversos.

Método: 90 pacientes, dosis de carga de clopidogrel: 600 mg. Se obtuvieron muestras de sangre basales y post-24 horas. La reactividad plaquetaria se estudió mediante medición de fosfoproteína estimulada por vasodilatadores por citometría de flujo. Se consideró baja respuesta al clopidogrel un índice de reactividad plaquetaria $\geq 50\%$. La presencia del CYP2C19*2 se identificó con enzima de restricción *Smal*.

Resultados: La media del índice de reactividad plaquetaria fue: $53.45 \pm 22.48\%$ en muestras basales y $57.14 \pm 23.08\%$ a 24 h ($p = 0.183$); 40% de los pacientes respondieron a clopidogrel, el resto de comportó como no-respondeedores, un 38%, mostró índices de reactividad plaquetaria entre 50 -70% y 22%, índices $> 70\%$. El polimorfismo CYP2C19*2 se encontró en 17% pacientes, con un 3.9% portadores de genotipo homozigótico AA.

Conclusiones: La respuesta a clopidogrel mostró amplia variabilidad entre pacientes, el 40% presentó respuesta de acuerdo con puntos de corte pre establecidos. Un 3.9% de los pacientes presentó genotipo AA. Consideramos que este es el primer estudio realizado en población mestizo-mexicana utilizado citometría de flujo para evaluar la respuesta a clopidogrel así como la tipificación genética de los pacientes.

© 2016 Instituto Nacional de Cardiología Ignacio Chávez. Publicado por Masson Doyma México S.A. Este es un artículo Open Access bajo la licencia CC BY-NC-ND (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Introduction

Platelets play a central role in the pathogenesis of acute coronary syndromes. Plaque rupture precipitates both the activation and aggregation of platelets with the formation of a thrombus, but this is avoided in patients with acute coronary syndromes as well as in those undergoing percutaneous coronary intervention (PCI) by using antiplatelet drugs to prevent abrupt vessel occlusion. Current guidelines recommend dual therapy with aspirin and P2Y12 antagonists,¹ and clopidogrel is the most widely used P2Y12 antagonist. Doses of up to 600 mg clopidogrel prior to PCI result in lower platelet aggregation and P-selectin expression with reduced cardiovascular events in patients with non-ST elevation coronary syndromes.² In recent years, however, resistance to aspirin or clopidogrel has gained importance,³ particularly the presence of a high inter-individual variability of response to the drug.⁴⁻⁹

The phosphorylation state of vasodilator-stimulated phosphoprotein (VASP) is a specific intracellular marker of residual P2Y12 receptor reactivity in patients treated with P2Y12 blockers, which is currently measured by flow cytometry and has also been correlated with ischemic risk.^{10,11} Unlike methods that include ADP-induced aggregation, the VASP phosphorylation assay does not include the contribution of the P2Y1 receptor to the overall response.¹⁰ The ratio of dephosphorylated and phosphorylated VASP is a specific measure of P2Y12 activity, which is expressed as the "platelet reactivity index" (PRI).

Genetic factors influence the absorption and/or the extent of metabolism of the prodrug clopidogrel to its active metabolite, and this contributes to the observed variability of response. To date, several polymorphisms have been related to high-dose treatment platelet reactivity, with the best established genetic factor being located within the CYP2C19 gene. A single nucleotide mutation (SNP) is

associated with a reduction in clopidogrel metabolism and with a slow metabolism phenotype,¹² although the frequency of slow metabolizers varies according to the study population. For example, in Asiatic populations, the frequency is as high as 13–23%, compared with 2–5% in Caucasians and 4–6% in African populations.^{13,14} The aim of this study was to evaluate platelet response to high-dose clopidogrel and to identify the presence of CYP2C19*2 carriers.

Methods

This descriptive, cross-sectional, observational clinical study was approved by the Institutional Research and Ethics Committee, and all subjects were literate adults who signed an informed consent form. Ninety consecutive patients were enrolled in the study between 2009 and 2012. The cohort consisted of patients with a diagnosis of non-ST acute coronary syndromes, stable angina, or those with a positive ischemia detection test in whom coronary angiography was performed. Exclusion criteria were ST elevation coronary syndromes, use of proton pump inhibitors, hepatic disease, a contraindication to antiplatelet use, and hemorrhagic diathesis. All patients received a 100 mg dose of aspirin at the time of the study; a 600 mg clopidogrel loading dose was administered 6–8 h prior to angiography in all cases. Blood samples were obtained from fasting patients. Basal samples were drawn once arterial access was obtained and a 6F sheath was placed via radial or femoral approach 6–8 h after the clopidogrel loading dose. A second sample was obtained by venipuncture 24 h after angiography. In all cases, 5 mL of blood were discarded from each sample drawn to avoid platelet activation.

Angiography and PCI

All patients underwent a diagnostic angiography. Patients undergoing PCI received unfractionated heparin (70 UI/kg). Stent placement was performed according to international guidelines,¹⁵ and drug-eluted stents or bare metal stents were implanted according to patient requirements. The sheath was removed and anticoagulation was stopped immediately at the end of the procedure in all cases. No GPIIb/IIIa inhibitors were used. A failed PCI was defined as a failure to obtain a residual stenosis <30% after stent placement, or a post-PCI anterograde TIMI 3 flow. All study subjects were followed up after 6 months.

VASP phosphorylation analysis

The VASP phosphorylation state was evaluated in all patients within 4 h after blood sampling using a standardized flow cytometric assay. Blood samples were collected using 3.8% sodium citrate as an anticoagulant, then incubated with prostaglandin E1 (PGE1) alone or PGE1 plus ADP for 10 min, and then fixed in paraformaldehyde for 5 min. Cells were permeabilized and labeled with a specific primary monoclonal anti-VASP antibody (clone 16C2) followed by a secondary fluorescein isothiocyanate-labeled polyclonal goat anti-mouse antibody and a platelet reactive marker with PE (anti-CD61PE) according to the manufacturer's

instructions of the VASP assay (PLATELET VASP/P2Y12 Biocytex, Marseille, France. The platelet mean fluorescence intensity (MFI) was determined using a flow cytometer (Beckman Coulter Epics Altra). The platelet population was identified by its distribution and at least 20,000 platelet events were analyzed. The platelet reactivity index (PRI) was then calculated from the MFI obtained in the presence of PGE1 alone (PGE1) or PGE1 and ADP simultaneously (PGE1 + ADP):

$$\text{PRI \%} = [(MFI(\text{PGE1}) - MFI(\text{PGE1} + \text{ADP})) / MFI(\text{PGE1})] \times 100.$$

The ratio is expressed as the percentage of mean platelet reactivity and is inversely proportional to the platelet inhibition obtained with clopidogrel.

Determination of polymorphisms

Genomic DNA from anticoagulated blood samples was extracted using the phenol-chloroform method, the quality of the obtained DNA was assessed according to standard procedures. The reaction mixture to amplify the sequences of interest containing the CYP2C19*2 polymorphism consists of 25 ng of DNA, 10 mM pH 9.0 Tris-HCl, 1.0 mM MgCl₂, 0.2 mM of each trypophosphate deoxynucleoside (dATP, dCTP, dGTP, dTTP), 0.5 U of Platinum Taq DNA polymerase high fidelity (Gibco-BRL, Life Technologies, Carlsbad, CA, USA) and 1 μM of 5'-CAGAGCTTGGCATATTGTATC-3' and 5'-GTAACACACAAACTAGTCAATG-3' primers specific for the CYP2C19*2 polymorphism in a final 25 μL volume.¹⁶ The amplification program was performed as follows: an initial denaturation at 94 °C for 5 min followed by 35 cycles (consisting of 45 s at 94 °C, 1 min at 60°, and 1 min at 72° by cycle) with a final extension of 72 °C for 7 min. The presence of CYP2C19*2 polymorphism was identified by digesting the amplification product of 316 bp with the restriction enzyme Sma I followed by standard 2% agarose gel electrophoresis. We assayed all samples by duplicate. Negative controls were included with every set of amplifications. The presence of an intact 316-bp fragment revealed the AA polymorphism, while a 109- and 207-bp fragment together represented no such polymorphism (GG). In cases where all three fragments were obtained, the patients were classified as heterozygotes (GA). The first amplicons of the CYP2C19 gene positive for GG, AA or GA polymorphism obtained from the samples, were sequenced by Macrogen USA in a Life Tech's AB 3730XL DNA Sequencing analyzer. The sequences were compared in the Gen Bank by the Blast algorithm to found the presence of the SNP and were included as positive controls in subsequent set of amplifications and digestions.

Statistical analysis

Descriptive statistical analyses were conducted using means and standard deviations for continuous variables. Percentages were applied to categorical variables. Variable distributions were analyzed using the Kolmogorov-Smirnov test, and discrete variables were analyzed with the χ² test. A two-tailed Student's *t*-test was used for non-paired continuous variables. Significance was set at an alpha level of

Table 1 Baseline characteristics.

	n = 90
Male, n (%)	71 (78.9)
Female, n (%)	19 (21.1)
Age (SD)	63.2 ± 9.8
BMI (kg/m ²) (SD)	26.6 ± 3.8
Smokers, n (%)	52 (61.1)
Dyslipidemia, n (%)	55 (61.1)
Hypertension, n (%)	66 (73.3)
Diabetes mellitus, n (%)	49 (54.4)
Family history of CAD, n (%)	42 (46.7)
Platelet count (SD)	223.8 ± 57.6
Percutaneous coronary intervention (stenting), n (%)	61 (67.8)
ACS (NSTEMI, UA)	60 (66.7)
Stable angina	24 (26.7)
Silent ischemia	6 (6.7)

ACS = acute coronary syndromes, NSTEMI = non ST elevation myocardial infarction, UA = unstable angina.

0.05. Analysis was conducted using the statistical package SPSS 18 for Windows (SPSS Inc., Chicago, IL, USA).

Results

Ninety patients were included in the study and their demographic, biological, and angiographic characteristics are summarized in **Table 1**. The mean age was 63.2 years, and 78.9% were male. As expected, there was a high incidence of cardiovascular risk factors, with 73.3% having hypertension and 54.4% having diabetes mellitus. The diagnosis on admission was non-ST elevation acute coronary syndromes in 60 individuals (66.7%), stable angina in 24 (26.7%), and silent ischemia in six cases (6.6%). PCI with stent placement was performed in 61 (67.8%) patients and drug-eluted stents were implanted in 36 (60%).

We analyzed platelet function using flow cytometric analysis of VASP phosphorylation in samples 6–8 h after a 600-mg bolus of clopidogrel was administered and 24 h

after the angiographic procedure. The mean PRI value was $53.45 \pm 22.48\%$ in the baseline sample and $57.14 \pm 23.08\%$ at 24 h ($p = 0.183$), with a large inter-individual variability observed in the biological response to clopidogrel (**Fig. 1**, Panels A and B). At 24 h, patients with dyslipidemia had a significantly better response to clopidogrel ($p = 0.030$), this was also found in older patients ($p = 0.050$). Lower platelet counts were also associated with a better response to the drug at 24 h ($p = 0.032$). No significant results were associated with other variables including body mass index and diabetes (**Tables 2 and 3**). No hemorrhagic complications were reported.

Clopidogrel response

We found that 36 patients (40%) were good responders, with a VASP-PRI < 50% in the baseline sample and 31 (37.8%) at 24 h ($p = \text{NS}$); a VASP-PRI greater than 50% (non-responders) was observed in the remaining patients (**Table 4**). VASP-PRI results were further divided into three groups as follows: group 1, VASP-PRI < 50%; group 2, VASP-PRI 50–70%; group 3, VASP-PRI > 70%. According to this as stated above, 40% of patients were good responders (group 1), the rest of the patients behaved as non-responders, 38% of them had a VASP-PRI 50–70% and 22% had VASP-PRI values greater than 70% (group 3). Dyslipidemia was associated with a significantly better response to the drug at 24 h ($p = 0.017$).

A change of status of clopidogrel response among the three groups was observed at 24 h; nine patients (11%) considered to have a good response in the first sample changed to group 2 (VASP-PRI 50–70%) and six (7.3%) moved to group 3 (VASP-PRI > 70%). In group 2 (VASP-PRI 50–70%), 12 patients (14.5%) were good responders at 24 h and nearly half of these (12.2%) had VASP-PRI values greater than 70%. Finally, in group 3 (VASP-PRI > 70%), only three individuals (3.7%) migrated into group 1 (VASP-PRI < 50%) and four (4.9%) into group 2 (VASP-PRI 50–70%). These findings did not follow a normal variation and were statistically significant ($p = 0.0039$; **Table 5**). Of all patients included in the present study, major adverse cardiac events (MACE) were only observed in four.




Figure 1 Basal sample PRI results. Panel A and 24 h sample panel B.

Table 2 Patient distribution according to VASP-PRI results (<50% and >50%) baseline and 24 h samples.

	% PRI baseline sample			% PRI 24 h		
	n (%)	SEM	P Value	n (%)	SEM	P Value
Gender						
Male	71 (78.9)	53.16 ± 2.7	0.894	63 (76.8)	56.73 ± 2.8	0.767
Female	19 (21.1)	52.38 ± 5.0		19 (23.2)	58.53 ± 5.6	
Angiography	29 (32.2)	51.39 ± 4.4	0.642	26 (31.7)	58.88 ± 4.7	0.646
PCI and stenting	61 (67.8)	53.75 ± 2.8	0.966	56 (68.3)	56.34 ± 3.1	0.758
Smokers	52 (57.8)	52.73 ± 3.3	0.134	48 (58.5)	57.85 ± 3.2	0.030*
Dyslipidemia	55 (61.1)	48.93 ± 3.2	0.964	51 (62.2)	53.38 ± 3.4	0.833
Diabetes	49 (54.4)	53.09 ± 2.9	0.530	46 (56.1)	56.67 ± 3.6	0.583
Hypertension	66 (73.3)	53.68 ± 2.9		60 (73.2)	56.17 ± 3.0	

SEM = standard error.

* p < 0.05.

Table 3 VASP-PRI and mean values, age, body mass index and platelet count baseline and 24 h samples.

	%PRI baseline n (%)	% PRI 24 h SEM	P Value	%PRI baseline n (%)	% PRI 24 h SEM	P Value
Age						
PRI < 50%	35 (38.9)	63.17 ± 1.4		30 (36.6)	66.87 ± 1.8	
PRI ≥ 50%	55 (61.1)	63.27 ± 1.4	0.962	52 (63.4)	60.79 ± 1.2	0.005*
BMI						
PRI < 50%	35 (38.9)	26.76 ± 0.6		30 (36.6)	27.19 ± 0.7	0.414
PRI ≥ 50%	55 (61.1)	26.56 ± 0.5	0.804	52 (63.4)	26.47 ± 0.5	(t)
Platelet count						
PRI < 50%	26 (28.9)	232.52 ± 13.2		21 (25.6)	201.48 ± 12.6	
PRI ≥ 50%	38 (42.2)	217.91 ± 8.1	0.323	36 (43.9)	235.85 ± 9.4	0.032*

SEM = standard error.

* p < 0.05.

CYP2C19*2 polymorphism and VASP-PRI analysis

DNA was obtained from 51 of the 90 patients, nine (17%) of whom were found to carry the CYP2C19*2 polymorphism. Of these, seven (13.7%) were heterozygotes (GA) and two (3.9%) were homozygous (AA); the remaining 42 patients (82.4%) had the wild-type genotype (GG).

When VASP-PRI results were analyzed in this group of patients, we found that the homozygous genotype had a mean VASP-PRI of 62.6% in the baseline sample and a VASP-PRI of 78.3% at 24 h (non-responders); these patients did not present MACE at follow-up ([Table 6](#)). Heterozygote patients (AG) had a mean VASP-PRI of 49.5% in the baseline sample and 60.4% at 24 h; finally, patients with the GG genotype showed VASP-PRI mean values of 57.3% and 62.5% in the

Table 4 Patients Response according to cut off value 50%.

VASP-PRI Value	Response type	Baseline sample		24 h Sample	
		n (%)	n (%)	n (%)	n (%)
<50%	Good response	36 (40)		31 (37.8)	
≥50%	Non responders	54 (60)		51 (62.2)	
	Total	90 (100)		82 (100)	

Table 5 Patient distribution on three groups baseline and 24 h samples.

	VASP-PRI 24 h			TOTAL <i>P</i> =0.039*
	<50%	50–70%	≥70%	
VASP-PRI Baseline Sample	<50%	15 (18.3%)	9 (11.0%)	6 (7.3%)
	50–70%	12 (14.5%)	12 (14.6%)	10 (12.2%)
	≥70%	3 (3.7%)	4 (4.9%)	11 (13.4%)
	TOTAL	30 (36.6%)	25 (30.5%)	27 (32.9%)

Table 6 CYP2C19*2 frequency (GA, AA) and VASP-PRI mean values.

Allele	Phenotype	Frequency n (%)	VASP-PRI First Sample± SD	VASP-PRI 24 h± SD
GG	Normal	42 (82.3)	57.3 ± 21.7	62.5 ± 19.7
GA	Intermediate	7 (13.7)	49.5 ± 35.5	60.4 ± 23.5
AA	Slow	2 (3.9)	62.6 ± 17.7	78.3 ± 0.40


baseline sample and 24 h, respectively ($p = \text{NS}$) (Fig. 2, Panels A and B).

Discussion

The present study was conducted in Mexican Mestizo patients in the central region of Mexico. This population is widely distributed across the country and represents about ninety three percent of the total population, and it is also present in the United States of America, where about the 66 percent of the Hispanic population is from Mexican descent. In Mexico, coronary artery disease is the second cause of death according to national statistics. To date, in this country clopidogrel is the antiplatelet drug most widely used in spite of the newer and more potent antiplatelet drugs. Our results are consistent with several publications that showed a large inter-individual variability. In a previous prospective study of patients undergoing successful

coronary artery stenting, a persistent increase in platelet reactivity measured by conventional aggregometry following a 300 mg clopidogrel loading dose was demonstrated in some patients, thus a higher loading dose was suggested.⁷ Similarly, enhanced platelet inhibition was observed during the post-stent period after a 300 mg loading dose was given 3–24 h prior to stenting, compared with a 75 mg dose given at the time of the procedure.⁸ Studies have also shown that doses of clopidogrel up to 600 mg enable a more potent antiplatelet effect to be achieved.¹⁷

Moreover, several studies have suggested a link between a low clopidogrel response or persistence of high platelet reactivity after treatment, as assessed by platelet assays, and post-PCI thrombotic events.^{18,19} These findings have determined a threshold of platelet reactivity that can be used to predict thrombotic events.^{20,21} Prospective studies reported that platelet reactivity above 50% according to the VASP index is associated with MACE after PCI and with stent thrombosis.²² Furthermore, recent trials

**Figure 2** CYP2C19 genotype effect on VASP-PRI value. Basal sample panel A and 24 h sample panel B.

demonstrated that increased platelet reactivity inhibition results in reduced MACE.²³ Bonello et al.²⁴ investigated the impact of a tailored clopidogrel loading dose according to platelet reactivity monitoring for stent thrombosis in patients undergoing nonemergency PCI, and observed a decrease in the primary endpoint without major bleeding complications. Although 60% of our patients presented a VASP-PRI value > 50%, we found no significant association with MACE, this could be related to the small sample size and also the percentage of PCI and stenting performed.

It is important to note that within groups of responders and non-responders, some patients demonstrated an appropriate response to clopidogrel in the first sample but showed an increased reactivity at 24 h in the present study. Similarly, Gurbel et al.²⁵ found that ~30% of patients were resistant to clopidogrel on days 1 and 5 post-stenting, and 15% were resistant at day 30. Based on these observations, they hypothesized that clopidogrel resistance was related to insufficient active metabolite generation following a 300 mg load and a 75 mg maintenance dose in selected patients. Further studies were conducted using a 600 mg loading dose, and higher platelet inhibition was observed at 24 h compared with patients receiving 300 mg. However, in the present study, we found that nearly 30% of patients had a VASP-PRI > 50% at 24 h despite receiving a 600 mg loading dose; moreover, patients considered to be good responders at the first sample changed their status to non-responders. This could be related to factors involving clopidogrel pharmacokinetics and deserve further study.

Our results showed that 3.9% of patients had the AA genotype, which is higher than the previously reported frequency of 0–1.45% in the Mexican Mestizo groups.²⁶ Although AA frequencies of 3.2% and 1.1% were reported in Mexican-Americans and in Colombian Mestizo individuals, respectively, neither of these studies investigated clopidogrel response.^{27,28} The absence of the polymorphism in the present study was not related to lower PRI values; indeed, high platelet reactivity was also found in such individuals, suggesting that the inter-individual response to clopidogrel must be influenced by other factors.

Hulot²⁹ previously showed that the presence of the CYP2C19*2 polymorphism was associated with a reduction in clopidogrel metabolism leading to a reduction in its antiplatelet effect. In the present study, homozygous (AA) patients showed higher, albeit non-significant, PRI values compared with heterozygote and wild-type patients. The presence of the CYP2C19*2 SNP in both alleles strongly suggests a poor metabolizer phenotype with reduced clopidogrel response. Heterozygote patients showed a variable behavior, which could be related to the expression of the alleles involved. Some studies not only observed the negative biological effects of the polymorphism but also its association with MACE in patients with PCI and stenting.³⁰ However, the presence of the CYP2C19*2 allele accounts for only 5–15%³¹ of clopidogrel response heterogeneity; moreover, the meta-analysis by Holmes³² concluded that there is no clinically significant association of the CYP2C19*2 genotype with cardiovascular events. The patients that presented with the AA polymorphism in our study did not develop MACE at the follow-up despite higher levels of VASP-PRI.

There are several limitations to our study. First, the sample size is small, which reflects the limited number of patients who agreed to participate, however previous studies have been conducted with a similar number of patients.^{7,17} Second, the patient sample is a heterogeneous mix of those with coronary artery disease, even though we aimed to evaluate the response to a 600 mg dose of clopidogrel in all clinical scenarios. Not every patient in the study received a stent and 40% were treated with bare metal stents; such patients may show an improved response to clopidogrel. Third, although VASP analysis is widely accepted, it is an expensive test requiring trained personnel and a flow cytometer, which may limit its widespread use in clinical practice. In conclusion, the response to a 600 mg loading dose of clopidogrel showed a wide variability in patients, with 40% responding to the drug according to previously established VASP-PRI cut-off values. Patients that initially responded to this loading dose showed a worsening of such response in the next 24 h, although no adverse cardiovascular events were related to this behavior. Of the 51 patients in whom genetic testing was performed, CYP2C19*2 was present in 17%. These data are similar to frequencies found in other populations and ethnic groups, but higher than the one reported in a similar population in Mexico. To our knowledge, this is the first study to evaluate the clopidogrel response using VASP-PRI analysis and correlation with CYP2C19 in Mexican mestizo population.

Ethical disclosures

Confidentiality of data. The authors declare that they have followed the protocols of their work center on the publication of patient data.

Protection of human and animal subjects. The authors declare that no experiments were performed on humans or animals for this study.

Right to privacy and informed consent. The authors declare that no patient data appear in this article.

Funding

All of the authors acknowledge that this project was financed by the CONACYT grant: CONACYT.SSA.IMSS.ISSSTE S008-2010-142034.

Conflict of interest

Dr. Carlos Areán has served as a consultant and/or speaker for Bristol Myers Squibb, MSD, Elly-Lilly and Bayer receiving less than 3000 USD honorarium. The rest of the authors declare having no competing interests.

Acknowledgement

We would like to thank the "Hospital General Dr. Miguel Silva" Cath Lab personnel for their support.

References

1. Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction; a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction). *Circulation*. 2007;116:148–304.
2. Cuisset T, Frere C, Quilici J, et al. Benefit of a 600mg loading dose of clopidogrel on platelet reactivity and clinical outcomes in patients with non-ST elevation acute coronary syndrome undergoing coronary stenting. *J Am Coll Cardiol*. 2006;48:1339–45.
3. Cattaneo M. Resistance to antiplatelet agents. *Thromb Res*. 2011;127:S61–3.
4. Järemo P, Lindahl TL, Fransson SG, et al. Individual variations of platelet inhibition after loading doses of clopidogrel. *J Intern Med*. 2002;252:233–8.
5. Angiolillo DJ, Fernandez-Ortíz A, Bernardo E, et al. Variability in individual responsiveness to clopidogrel: clinical implications, management and future perspectives. *J Am Coll Cardiol*. 2007;49:1505–16.
6. Ferreiro JL, Angiolillo D. Clopidogrel response variability: current status and future directions. *Thromb Haemost*. 2009;102:7–14.
7. Gurbel PA, Malinin AI, Callahan KP, et al. Effect of loading with clopidogrel at the time of coronary stenting on platelet aggregation and glycoprotein IIb/IIIa expression and platelet-leukocyte aggregate formation. *Am J Cardiol*. 2002;90:312–5.
8. Gurbel PA, Cummings CC, Bell CR, et al. Plavix Reduction Of New Thrombus Occurrence (PRONTO) trial. Onset and extent of platelet inhibition by clopidogrel loading in patients undergoing elective coronary stenting: the Plavix Reduction Of New Thrombus Occurrence (PRONTO) trial. *Am Heart J*. 2003;145:239–47.
9. Gurbel PA, Bliden KP, Hiatt BL, et al. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. *Circulation*. 2003;107:2908–13.
10. Aleil B, Ravanat C, Cazenave JP, et al. Flow cytometric analysis of intraplatelet VASP phosphorylation for the detection of clopidogrel resistance in patients with ischemic cardiovascular diseases. *J Thromb Haemost*. 2005;3:85–92.
11. Gurbel PA, Becker RC, Mann KG, et al. Platelet function monitoring in patients with coronary artery disease. *J Am Coll Cardiol*. 2007;50:1822–34.
12. Lee SJ. Clinical application of CYP2C19 pharmacogenetics toward more personalized medicine. *Front Genet*. 2013;3:318.
13. Zand N, Tajik N, Hoomand M, et al. Allele frequency of CYP2C19 gene polymorphisms in healthy Iranian population. *Iran J Pharmacol Ther*. 2005;4:125–8.
14. Fukushima-Uesaka H, Saito Y, Maekawa K, et al. Variations and haplotypes of CYP2C19 in Japanese population. *Drug Metab Pharmacokinet*. 2005;20:300–7.
15. Levine GN, Bates ER, Bailey SR, et al. 2011 ACC/AHA/SCAI Guidelines for Percutaneous Coronary Intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. *J Am Coll Cardiol*. 2011;58:e44–122.
16. Sambrook J, Russel DW. Molecular cloning a laboratory manual. 3rd ed. Cold Spring Harvor, NY: Cold Spring Harvor Laboratory Press; 2001.
17. Siller-Matula JM, Huber K, Christ G, et al. Impact of clopidogrel loading dose on clinical outcome in patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis. *Heart*. 2011;97:98–105.
18. Matetzky S, Shenkman B, Guetta V, et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. *Circulation*. 2004;109:3171–5.
19. Geisler T, Langer H, Wydymus M, et al. Low response to clopidogrel is associated with cardiovascular outcome after coronary stent implantation. *Eur Heart J*. 2006;27:2420–5.
20. Barragan P, Bouvier JL, Roquebert PO, et al. Resistance to thienopyridines: clinical detection of coronary stent thrombosis by monitoring of vasodilator-stimulated phosphoprotein phosphorylation. *Catheter Cardiovasc Interv*. 2003;59:295–302.
21. George F, Barragan P, Camoin-Jau L. Vasodilator-stimulated phosphoprotein phosphorylation analysis prior to percutaneous coronary intervention for exclusion of postprocedural major adverse cardiovascular events. *J Thromb Haemost*. 2007;5:1630–6.
22. Blöndt R, Stellbrink K, de Taeye A, et al. The significance of vasodilator stimulated phosphoprotein for risk stratification of stent thrombosis. *Thromb Haemost*. 2007;98:1329–34.
23. Bonello L, Tantry US, Marcucci R, et al., Working Group on High On-Treatment Platelet Reactivity. Consensus and future directions on the definition of high on treatment platelet reactivity to adenosine diphosphate. *J Am Coll Cardiol*. 2010;56:919–318.
24. Bonello L, Camoin-Jau L, Armero S, et al. Tailored clopidogrel loading dose according to platelet reactivity monitoring to prevent acute and subacute stent thrombosis. *Am J Cardiol*. 2009;103:5–10.
25. Gurbel P, Tantry U. Clopidogrel resistance. *Thromb Res*. 2007;120:311–21.
26. Salazar-Flores J, Torres-Reyes LA, Martínez-Cortés G, et al. Distribution of CYP2D6 and CYP2C19 polymorphisms associated with poor metabolizer phenotype in five Amerindian groups and western Mestizos from Mexico. *Genet Test Mol Biomark*. 2012 Sep;16:1098–104.
27. Luo HR, Poland RE, Link KM, et al. Genetic polymorphism of cytochrome P450 2C19 in Mexican Americans; a cross-ethnic comparative study. *Clin Pharmacol Ther*. 2006;80:133–40.
28. Isaza C, Henao J, Martínez JH, et al. Phenotype-genotype analysis of CYP2C19 in Colombians mestizo individuals. *BMC Clin Pharmacol*. 2007;7:6.
29. Hulot JS, Bura A, Villard E, et al. Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. *Blood*. 2006;108:2244–7.
30. Mega J, Close SL, Wiviott SD, et al. Cytochrome P 450 polymorphisms and response to clopidogrel. *N Engl J Med*. 2009;360:354–62.
31. Bouman HJ, Harmsze AM, Van Werkum JW, et al. Variability in on-treatment platelet reactivity explained by CYP2C19*2 genotype is modest in clopidogrel pre-treated patients undergoing coronary stenting. *Heart*. 2011;97:1239–44.
32. Holmes MV, Perel P, Shah T, et al. CYP 2C19 genotype: clopidogrel metabolism, platelet function and cardiovascular events. A systematic review and meta-analysis. *JAMA*. 2011;306:2704–14.